UniQure’s haemophilia B therapy picks up PRIME status
admin 26th April 2017 Uncategorised 0uniQure’s investigational gene therapy for patients with the blood clotting disorder haemophilia B has been awarded PRIME status by European regulators, potentially placing the treatment on a faster path to approval.
More: UniQure’s haemophilia B therapy picks up PRIME status
Source: News